|Day Low/High||42.55 / 43.02|
|52 Wk Low/High||37.12 / 46.47|
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.
Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
The Senator says that Gottlieb's appointment to the company's board smacks of the Washington revolving door that has become prevalent.
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG.
Shares of Pfizer rise after the company announces positive results in a late-stage, non-steroid trial of a treatment for chronic dermatitis, or eczema, in kids.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the efficacy and safety of intravenous (IV) sildenafil when added to inhaled nitric oxide (iNO) for the treatment of newborns with Persistent Pulmonary Hypertension (PPHN) did not meet...
An analyst at Baird says a Pfizer gene therapy drug had safety and efficacy issues during a study.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
Pfizer Inc. (NYSE:PFE) will present initial Phase 1b clinical data on PF-06939926, an investigational gene therapy to potentially treat Duchenne muscular dystrophy (DMD) at the 25th Annual Parent Project Muscular Dystrophy (PPMD) Connect Conference in...
Pfizer Inc. (NYSE:PFE) today announced the United States (U.
Pfizer Inc. (NYSE:PFE) today announced the election of Dr.
The Board of Directors of Pfizer Inc. today declared a 36-cent third-quarter 2019 dividend on the company's common stock, payable September 3, 2019, to holders of the Common Stock of record at the close of business on August 2, 2019.
Jim Cramer explains the art and science of technical analysis.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA ® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility...
The names include a veterinary drug concern plus companies with successful drugs on the market.
These two firms have successful drugs and could make nice additions for larger companies.
NEW YORK, June 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (NASDAQ: ARRY) in connection with the proposed...
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.